Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody–drug conjugates

Design of Self-Immolative Linkers for Tumour-Activated Prodrug Therapy

(2013) I. Tranoy-Opalinski et al.   Anti-Cancer Agents in Medicinal Chemistry

Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection

(2009) A. G. Polson et al.   CANCER RESEARCH

Antibody-Drug Conjugate Targets

(2009) B. Teicher   CURRENT CANCER DRUG TARGETS

Novel Peptide Linkers for Highly Potent Antibody−Auristatin Conjugate

(2008) Svetlana O. Doronina et al.   BIOCONJUGATE CHEMISTRY

Antibody-Drug Conjugates for Cancer Therapy

(2008) Paul J. Carter et al.   CANCER JOURNAL

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

Newer Cytotoxic Agents: Attacking Cancer Broadly

(2008) B. A. Teicher   CLINICAL CANCER RESEARCH

Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs

(2007) Ravi V. J. Chari   ACCOUNTS OF CHEMICAL RESEARCH